Format

Send to

Choose Destination
  • The following term was ignored: ;
  • See the search details.
Cancer Sci. 2018 Mar;109(3):531-541. doi: 10.1111/cas.13485. Epub 2018 Feb 14.

Cancer immunotherapy-targeted glypican-3 or neoantigens.

Author information

1
Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
2
Department of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.

Abstract

Immune checkpoint inhibitors have ushered in a new era in cancer therapy, although other therapies or combinations thereof are still needed for many patients for whom these drugs are ineffective. In this light, we have identified glypican-3 an HLA-24, HLA-A2 restriction peptide with extreme cancer specificity. In this paper, we summarize results from a number of related clinical trials showing that glypican-3 peptide vaccines induce specific CTLs in most patients (UMIN Clinical Trials Registry: UMIN000001395, UMIN000005093, UMIN000002614, UMN000003696, and UMIN000006357). We also describe the current state of personalized cancer immunotherapy based on neoantigens, and assess, based on our own research and experience, the potential of such therapy to elicit cancer regression. Finally, we discuss the future direction of cancer immunotherapy.

KEYWORDS:

CAR-transduced T-cell therapy; TCR-transduced T-cell therapy; cancer vaccine; glypican-3; neoantigen

PMID:
29285841
PMCID:
PMC5834776
DOI:
10.1111/cas.13485
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center